D. Vaudry, A. Falluel-morel, S. Bourgault, M. Basille, D. Burel et al., Pituitary adenylate cyclaseactivating polypeptide and its receptors: 20 years after the discovery, Pharmacol Rev, vol.61, pp.283-357, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02058111

J. Fahrenkrug and P. Vip, Results Probl Cell Differ, vol.50, pp.221-255, 2010.

A. J. Harmar, J. Fahrenkrug, I. Gozes, M. Laburthe, V. May et al., Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1, Br J Pharmacol, vol.166, pp.4-17, 2012.

M. Delgado, D. Pozo, and D. Ganea, The significance of vasoactive intestinal peptide in immunomodulation, Pharmacol Rev, vol.56, pp.249-90, 2004.

M. Delgado, E. J. Munoz-elias, Y. Kan, I. Gozes, M. Fridkin et al., Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun, J Biol Chem, vol.273, pp.31427-31463, 1998.

M. Delgado, C. Martinez, M. C. Johnson, R. P. Gomariz, and D. Ganea, Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes, J Neuroimmunol, vol.68, pp.27-38, 1996.

M. Delgado, A. Reduta, V. Sharma, and D. Ganea, VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells, J Leukoc Biol, vol.75, pp.1122-1152, 2004.

D. Pozo, M. Delgado, C. Martinez, R. P. Gomariz, J. M. Guerrero et al., Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages, Biochim Biophys Acta, vol.1359, pp.250-62, 1997.

M. Delgado, D. Pozo, C. Martinez, J. Leceta, J. R. Calvo et al., Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies, J Immunol, vol.162, pp.2358-67, 1999.

C. Martinez, M. Delgado, D. Pozo, J. Leceta, J. R. Calvo et al., Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages, J Leukoc Biol, vol.63, pp.591-601, 1998.

M. Delgado, E. J. Munoz-elias, R. P. Gomariz, and D. Ganea, VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells, J Neuroimmunol, vol.96, pp.167-81, 1999.

A. Chorny, E. Gonzalez-rey, N. Varela, G. Robledo, and M. Delgado, Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions, Regul Pept, vol.137, pp.67-74, 2006.

M. Delgado, VIP: a very important peptide in T helper differentiation, Trends Immunol, vol.24, pp.221-225, 2003.

J. K. Voice, G. Dorsam, R. C. Chan, C. Grinninger, Y. Kong et al., Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide, Regul Pept, vol.109, pp.199-208, 2002.

M. Delgado, J. Leceta, R. P. Gomariz, and D. Ganea, Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression, J Immunol, vol.163, pp.3629-3664, 1999.

M. Delgado, J. Leceta, W. Sun, R. P. Gomariz, and D. Ganea, VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression, Ann N Y Acad Sci, vol.921, pp.68-78, 2000.

M. Delgado, E. Gonzalez-rey, and D. Ganea, VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells, FASEB J, vol.18, pp.1453-1458, 2004.

D. Fabricius, M. S. O'dorisio, S. Blackwell, and B. Jahrsdorfer, Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide, J Immunol, vol.177, pp.5920-5927, 2006.

V. Sharma, M. Delgado, and D. Ganea, VIP protects Th2 cells by downregulating granzyme B expression, Ann N Y Acad Sci, vol.1070, pp.540-544, 2006.

V. Sharma, M. Delgado, and D. Ganea, Granzyme B, a new player in activationinduced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors, J Immunol, vol.176, pp.97-110, 2006.

M. Delgado, J. Leceta, and D. Ganea, Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells, FASEB J, vol.16, pp.1844-1850, 2002.

M. Delgado, A. Chorny, E. Gonzalez-rey, and D. Ganea, Vasoactive intestinal peptide generates CD4 + CD25+ regulatory T cells in vivo, J Leukoc Biol, vol.78, pp.1327-1365, 2005.

E. Gonzalez-rey, A. Chorny, A. Fernandez-martin, D. Ganea, and M. Delgado, Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells, Blood, vol.107, pp.3632-3640, 2006.

E. Gonzalez-rey and M. Delgado, Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis, Trends Mol Med, vol.13, pp.241-51, 2007.

E. Gonzalez-rey and M. Delgado, Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide, Gastroenterology, vol.131, pp.1799-811, 2006.

E. Gonzalez-rey, A. Fernandez-martin, A. Chorny, and M. Delgado, Vasoactive intestinal peptide induces CD4+, CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis, Arthritis Rheum, vol.54, pp.864-76, 2006.

A. Fernandez-martin, E. Gonzalez-rey, A. Chorny, D. Ganea, and M. Delgado, Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis, Eur J Immunol, vol.36, pp.318-344, 2006.

M. Delgado, C. Abad, C. Martinez, J. Leceta, and R. P. Gomariz, Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease, Nat Med, vol.7, pp.563-571, 2001.

C. Abad, C. Martinez, M. G. Juarranz, A. Arranz, J. Leceta et al., Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease, Gastroenterology, vol.124, pp.961-71, 2003.

E. Gonzalez-rey, A. Fernandez-martin, A. Chorny, J. Martin, D. Pozo et al., Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses, Am J Pathol, vol.168, pp.1179-88, 2006.

M. Rangachari and V. K. Kuchroo, Using EAE to better understand principles of immune function and autoimmune pathology, J Autoimmun, vol.45, pp.31-40, 2013.

B. Hemmer, M. Kerschensteiner, and T. Korn, Role of the innate and adaptive immune responses in the course of multiple sclerosis, Lancet Neurol, vol.14, pp.406-425, 2015.

Y. V. Tan, C. Abad, Y. Wang, R. Lopez, and J. A. Waschek, VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses, Brain Behav Immun, vol.44, pp.167-75, 2015.

C. Abad, Y. V. Tan, R. Lopez, H. Nobuta, H. Dong et al., Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis, Proc Natl Acad Sci U S A, vol.107, pp.19555-60, 2010.

C. Abad, Y. Tan, G. Cheung-lau, H. Nobuta, and J. A. Waschek, VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses, PLoS One, vol.7, p.36922, 2012.

C. Abad, G. Cheung-lau, A. Coute-monvoisin, and J. A. Waschek, Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis, Neuroimmunomodulation, vol.22, pp.203-215, 2015.

D. Fabricius, B. Karacay, D. Shutt, W. Leverich, B. Schafer et al., Characterization of intestinal and pancreatic dysfunction in VPAC1-null mutant mouse, Pancreas, vol.40, pp.861-71, 2011.

Y. V. Tan, C. Abad, R. Lopez, H. Dong, S. Liu et al., Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis, Proc Natl Acad Sci U S A, vol.106, pp.2012-2019, 2009.

P. Gourlet, D. Neef, P. Cnudde, J. Waelbroeck, M. Robberecht et al., In vitro properties of a high affinity selective antagonist of the VIP1 receptor, Peptides, vol.18, pp.1555-60, 1997.

K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, vol.25, pp.402-410, 2001.

P. Kivisakk, J. Imitola, S. Rasmussen, W. Elyaman, B. Zhu et al., Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis, Ann Neurol, vol.65, pp.457-69, 2009.

D. R. Huang, J. Wang, P. Kivisakk, B. J. Rollins, and R. M. Ransohoff, Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis, J Exp Med, vol.193, pp.713-739, 2001.

B. T. Fife, G. B. Huffnagle, W. A. Kuziel, and W. J. Karpus, CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis, J Exp Med, vol.192, pp.899-905, 2000.

M. Delgado, R. P. Gomariz, C. Martinez, C. Abad, and J. Leceta, Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock, Eur J Immunol, vol.30, pp.3236-3282, 2000.

M. Lara-marquez, O. 'dorisio, M. , O. 'dorisio, T. Shah et al., Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells, J Immunol, vol.166, pp.2522-2552, 2001.

A. Storka, B. Burian, G. Fuhrlinger, C. B. Sun, T. Crevenna et al., VPAC1 receptor expression in peripheral blood mononuclear cells in a human endotoxemia model, J Transl Med, vol.11, p.117, 2013.

R. J. Hermann, T. Van-der-steen, E. E. Vomhof-dekrey, A. , S. Wanjara et al., Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry, J Immunol Methods, vol.376, pp.20-31, 2012.

E. E. Vomhof-dekrey, R. J. Hermann, M. F. Palmer, K. D. Benton, A. R. Sandy et al., TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells, Brain Behav Immun, vol.22, pp.1032-1072, 2008.

E. E. Vomhof-dekrey and G. P. Dorsam, Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells, Brain Behav Immun, vol.22, pp.1024-1055, 2008.

E. Cocco, F. Paladini, G. Macino, V. Fulci, M. T. Fiorillo et al., The expression of vasoactive intestinal peptide receptor 1 is negatively modulated by microRNA 525-5p, PLoS One, vol.5, p.12067, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00543355

J. L. Herrera, E. Gonzalez-rey, R. Fernandez-montesinos, F. J. Quintana, R. Najmanovich et al., Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages, J Cell Mol Med, vol.13, pp.3209-3226, 2009.

N. Kawakami, I. Bartholomaus, M. Pesic, and M. Mues, An autoimmunity odyssey: how autoreactive T cells infiltrate into the CNS, Immunol Rev, vol.248, pp.140-55, 2012.

J. A. Johnston, D. D. Taub, A. R. Lloyd, K. Conlon, J. J. Oppenheim et al., Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide, J Immunol, vol.153, pp.1762-1770, 1994.

M. Xia, D. Leppert, S. L. Hauser, S. P. Sreedharan, P. J. Nelson et al., Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane, J Immunol, vol.156, pp.160-167, 1996.

P. Schratzberger, A. Geiseler, S. Dunzendorfer, N. Reinisch, C. M. Kahler et al., Similar involvement of VIP receptor type I and type II in lymphocyte chemotaxis, J Neuroimmunol, vol.87, pp.73-81, 1998.

S. T. Dorsam, E. Vomhof-dekrey, R. J. Hermann, J. S. Haring, T. Van-der-steen et al., Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells, Mol Immunol, vol.47, pp.1181-94, 2010.

J. Yang, Q. D. Shi, T. B. Song, G. F. Feng, W. J. Zang et al., Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro, Peptides, vol.42, pp.105-116, 2013.

A. Castorina, S. Giunta, V. Mazzone, V. Cardile, D. 'agata et al., Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells, Peptides, vol.31, pp.2276-83, 2010.

K. M. Joo, Y. H. Chung, M. K. Kim, R. H. Nam, B. L. Lee et al., Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain, J Comp Neurol, vol.476, pp.388-413, 2004.

M. Delgado, Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia, Biochem Biophys Res Commun, vol.293, pp.771-777, 2002.

Y. Arima, M. Harada, D. Kamimura, J. H. Park, F. Kawano et al., Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier, Cell, vol.148, pp.447-57, 2012.

C. Martinez, M. Delgado, D. Pozo, J. Leceta, J. R. Calvo et al., VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies, J Neuroimmunol, vol.85, pp.155-67, 1998.

A. Reboldi, C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli et al., C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE, Nat Immunol, vol.10, pp.514-537, 2009.

B. Kis, C. S. Abraham, M. A. Deli, H. Kobayashi, M. Niwa et al., Adrenomedullin, an autocrine mediator of blood-brain barrier function, Hypertens Res, vol.26, pp.61-70, 2003.

B. Kis, L. Chen, Y. Ueta, and D. W. Busija, Autocrine peptide mediators of cerebral endothelial cells and their role in the regulation of blood-brain barrier, Peptides, vol.27, pp.211-233, 2006.

D. R. Staines, E. W. Brenu, and S. Marshall-gradisnik, Postulated role of vasoactive neuropeptide-related immunopathology of the blood brain barrier and Virchow-Robin spaces in the aetiology of neurological-related conditions, Mediators Inflamm, p.792428, 2008.

J. M. Hansen, J. Sitarz, S. Birk, A. M. Rahmann, P. S. Oturai et al., Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers, Cephalalgia, vol.26, pp.992-1003, 2006.

H. W. Schytz, S. Birk, T. Wienecke, C. Kruuse, J. Olesen et al., PACAP38 induces migraine-like attacks in patients with migraine without aura, Brain, vol.132, pp.16-25, 2009.

M. Yadav, M. C. Huang, and E. J. Goetzl, VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis, Cell Immunol, vol.267, pp.124-156, 2011.

D. Maimone, C. Cioni, S. Rosa, G. Macchia, F. Aloisi et al., Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1 beta and TNF alpha, J Neuroimmunol, vol.47, pp.73-81, 1993.

P. Rameshwar, P. Gascon, H. S. Oh, T. N. Denny, G. Zhu et al., Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor, Exp Hematol, vol.30, pp.1001-1010, 2002.

L. Souza-moreira, M. Morell, V. Delgado-maroto, M. Pedreno, L. Martinez-escudero et al., Paradoxical effect of cortistatin treatment and its deficiency on experimental autoimmune encephalomyelitis, J Immunol, vol.191, pp.2144-54, 2013.

D. H. Loh, C. Abad, C. S. Colwell, and J. A. Waschek, Vasoactive intestinal peptide is critical for circadian regulation of glucocorticoids, Neuroendocrinology, vol.88, pp.246-55, 2008.